$6.39
-0.60[-8.58%]
At close: Apr 23
$6.39
0[0.00%]
PreMarket: 5:24PM EDT
Rani Therapeutics Hldgs
(NASDAQ:RANI)Rani Therapeutics Hldgs Stock (NASDAQ:RANI), Analyst Ratings, Price Targets, Predictions
Rani Therapeutics Holdings Inc has a consensus price target of $17.22, established from looking at the 19 latest analyst ratings. The last 3 analyst ratings were released from Canaccord Genuity, HC Wainwright & Co., and Wedbush on March 27, 2024, March 25, 2024, and February 6, 2024. With an average price target of $9.67 between Canaccord Genuity, HC Wainwright & Co., and Wedbush, there's an implied 51.28% upside for Rani Therapeutics Holdings Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Canaccord Genuity
HC Wainwright & Co.
Wedbush
B of A Securities
UBS
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Rani Therapeutics Hldgs
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/27/2024 | RANI | Buy Now | Rani Therapeutics Hldgs | $6.39 | 40.85% | Canaccord Genuity | Edward Nash | $21 → $9 | Maintains | Buy | Get Alert |
| 03/25/2024 | RANI | Buy Now | Rani Therapeutics Hldgs | $6.39 | 87.79% | HC Wainwright & Co. | Mitchell Kapoor | $16 → $12 | Maintains | Buy | Get Alert |
| 02/06/2024 | RANI | Buy Now | Rani Therapeutics Hldgs | $6.39 | 25.2% | Wedbush | Andreas Argyrides | → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 11/09/2023 | RANI | Buy Now | Rani Therapeutics Hldgs | $6.39 | 150.39% | HC Wainwright & Co. | Mitchell Kapoor | $20 → $16 | Maintains | Buy | Get Alert |
| 09/20/2023 | RANI | Buy Now | Rani Therapeutics Hldgs | $6.39 | 212.99% | HC Wainwright & Co. | Mitchell Kapoor | → $20 | Reiterates | Buy → Buy | Get Alert |
| 09/08/2023 | RANI | Buy Now | Rani Therapeutics Hldgs | $6.39 | 212.99% | HC Wainwright & Co. | Mitchell Kapoor | → $20 | Reiterates | Buy → Buy | Get Alert |
| 08/21/2023 | RANI | Buy Now | Rani Therapeutics Hldgs | $6.39 | 166.04% | B of A Securities | Geoff Meacham | $19 → $17 | Maintains | Buy | Get Alert |
| 08/17/2023 | RANI | Buy Now | Rani Therapeutics Hldgs | $6.39 | 212.99% | Wedbush | Andreas Argyrides | → $20 | Reiterates | Outperform → Outperform | Get Alert |
| 08/14/2023 | RANI | Buy Now | Rani Therapeutics Hldgs | $6.39 | 212.99% | HC Wainwright & Co. | Mitchell Kapoor | $22 → $20 | Maintains | Buy | Get Alert |
| 06/06/2023 | RANI | Buy Now | Rani Therapeutics Hldgs | $6.39 | 244.29% | HC Wainwright & Co. | Mitchell Kapoor | → $22 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | RANI | Buy Now | Rani Therapeutics Hldgs | $6.39 | 244.29% | HC Wainwright & Co. | Mitchell Kapoor | → $22 | Reiterates | Buy → Buy | Get Alert |
| 03/23/2023 | RANI | Buy Now | Rani Therapeutics Hldgs | $6.39 | 244.29% | HC Wainwright & Co. | Mitchell Kapoor | → $22 | Reiterates | → Buy | Get Alert |
| 10/11/2022 | RANI | Buy Now | Rani Therapeutics Hldgs | $6.39 | 134.74% | UBS | Ashwani Verma | → $15 | Initiates | → Buy | Get Alert |
| 07/27/2022 | RANI | Buy Now | Rani Therapeutics Hldgs | $6.39 | 244.29% | HC Wainwright & Co. | Mitchell Kapoor | → $22 | Initiates | → Buy | Get Alert |
| 06/13/2022 | RANI | Buy Now | Rani Therapeutics Hldgs | $6.39 | 338.18% | Wedbush | Andreas Argyrides | → $28 | Initiates | → Outperform | Get Alert |
| 08/25/2021 | RANI | Buy Now | Rani Therapeutics Hldgs | $6.39 | 275.59% | BTIG | Robert Hazlett | — | Initiates | → Buy | Get Alert |
| 08/24/2021 | RANI | Buy Now | Rani Therapeutics Hldgs | $6.39 | 259.94% | B of A Securities | — | — | Initiates | → Buy | Get Alert |
| 08/24/2021 | RANI | Buy Now | Rani Therapeutics Hldgs | $6.39 | 259.94% | Cantor Fitzgerald | Brandon Folkes | — | Initiates | → Overweight | Get Alert |
| 08/24/2021 | RANI | Buy Now | Rani Therapeutics Hldgs | $6.39 | 275.59% | Stifel | Annabel Samimy | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Rani Therapeutics Hldgs (RANI)?
The latest price target for Rani Therapeutics Hldgs (NASDAQ: RANI) was reported by Canaccord Genuity on March 27, 2024. The analyst firm set a price target for $9.00 expecting RANI to rise to within 12 months (a possible 40.85% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Rani Therapeutics Hldgs (RANI)?
The latest analyst rating for Rani Therapeutics Hldgs (NASDAQ: RANI) was provided by Canaccord Genuity, and Rani Therapeutics Hldgs maintained their buy rating.
When was the last upgrade for Rani Therapeutics Hldgs (RANI)?
There is no last upgrade for Rani Therapeutics Hldgs.
When was the last downgrade for Rani Therapeutics Hldgs (RANI)?
There is no last downgrade for Rani Therapeutics Hldgs.
When is the next analyst rating going to be posted or updated for Rani Therapeutics Hldgs (RANI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rani Therapeutics Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rani Therapeutics Hldgs was filed on March 27, 2024 so you should expect the next rating to be made available sometime around March 27, 2025.
Is the Analyst Rating Rani Therapeutics Hldgs (RANI) correct?
While ratings are subjective and will change, the latest Rani Therapeutics Hldgs (RANI) rating was a maintained with a price target of $21.00 to $9.00. The current price Rani Therapeutics Hldgs (RANI) is trading at is $6.39, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.